Oklahoma 2024 Regular Session

Oklahoma Senate Bill SB217 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1
2	2
3	3
4	4	Req. No. 1358 Page 1 1
5	5	2
6	6	3
7	7	4
8	8	5
9	9	6
10	10	7
11	11	8
12	12	9
13	13	10
14	14	11
15	15	12
16	16	13
17	17	14
18	18	15
19	19	16
20	20	17
21	21	18
22	22	19
23	23	20
24	24	21
25	25	22
26	26	23
27	27	24
28	28	1
29	29	2
30	30	3
31	31	4
32	32	5
33	33	6
34	34	7
35	35	8
36	36	9
37	37	10
38	38	11
39	39	12
40	40	13
41	41	14
42	42	15
43	43	16
44	44	17
45	45	18
46	46	19
47	47	20
48	48	21
49	49	22
50	50	23
51	51	24
52	52
53	53	STATE OF OKLAHOMA
54	54
55	55	1st Session of the 59th Legislature (2023)
56	56
57	57	SENATE BILL 217 By: Hamilton
58	58
59	59
60	60
61	61
62	62
63	63	AS INTRODUCED
64	64
65	65	An Act relating to health care; requiring licensed
66	66	practitioners to offer pharmacogenomic test prior to
67	67	prescription of psyc hotropic drugs; requiring certain
68	68	disclosures and obtainment of informed consent;
69	69	directing order and administration of pharmacogenomic
70	70	test; providing for codificat ion; and providing an
71	71	effective date.
72	72
73	73
74	74
75	75
76	76
77	77	BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOM A:
78	78	SECTION 1. NEW LAW A new section of law to be codified
79	79	in the Oklahoma Statutes as Section 7201 of Title 63, unless there
80	80	is created a duplication in numbering, reads a s follows:
81	81	A. A licensed practitioner shall, prior to the prescription of
82	82	any psychotropic drug to a patient, offer to administer a
83	83	pharmacogenomic test to the patien t for the purpose of guiding the
84	84	decisions of the licensed practitioner with respect to how the
85	85	patient’s genes may react to certain medicat ions.
86	86	B. The licensed practitioner shall , to the best of the licensed
87	87	practitioner’s knowledge, inform the patient of the efficacy of
88	88	pharmacogenomic testing. The licensed practitioner shall inform the
89	89
90	90
91	91	Req. No. 1358 Page 2 1
92	92	2
93	93	3
94	94	4
95	95	5
96	96	6
97	97	7
98	98	8
99	99	9
100	100	10
101	101	11
102	102	12
103	103	13
104	104	14
105	105	15
106	106	16
107	107	17
108	108	18
109	109	19
110	110	20
111	111	21
112	112	22
113	113	23
114	114	24
115	115	1
116	116	2
117	117	3
118	118	4
119	119	5
120	120	6
121	121	7
122	122	8
123	123	9
124	124	10
125	125	11
126	126	12
127	127	13
128	128	14
129	129	15
130	130	16
131	131	17
132	132	18
133	133	19
134	134	20
135	135	21
136	136	22
137	137	23
138	138	24
139	139
140	140	patient of whether or not the pharmacogenomic test to be
141	141	administered is approved by the Food and Drug Administration. The
142	142	licensed practitioner shall obtain the patient ’s informed consent
143	143	prior to ordering a pharmacogenomic test. If the practitioner is
144	144	aware of the cost of the pharmacogenomic test, the practitioner
145	145	shall provide an estimate to the patient of such cost.
146	146	C. If a patient provides informed consent to receive a
147	147	pharmacogenomic test, the lic ensed practitioner shall o rder the
148	148	pharmacogenomic test and administer such test to the patient prior
149	149	to the prescription of any psychotropic medication .
150	150	SECTION 2. This act shall become effective November 1, 202 3.
151	151
152	152	59-1-1358 DC 1/9/2023 5:41:08 PM